Precision Medicine

Takeda and MD Anderson Collaborate to Accelerate Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

HOUSTON & OSAKA, Japan–(BUSINESS WIRE)–The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other …

Read More »

Siemens Healthineers Partners with Quanterix for Access to Nf-L Antibodies for Development of Nf-L Assays

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will …

Read More »

Ambry Genetics Published Data that Finds Adding RNA Genetic Testing Provides Better Results for Patients who Receive DNA Testing for Hereditary Cancer Risk

ALISO VIEJO, Calif., Oct. 23, 2019 /PRNewswire/ — Ambry Genetics® (Ambry), a leading clinical genetics company, announced today the publication in JAMA Network Open of a study on retrospective RNA genetic testing for hereditary cancer risk. The study reveals that adding RNA testing could provide more accurate results for one …

Read More »

LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial

STONY BROOK, N.Y.–(BUSINESS WIRE)–LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform demonstrated superior correlation over Prostate Specific Antigen (PSA) in an ongoing Phase II trial in recurrent prostate cancer. Most notably, the concentration of …

Read More »

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

CAMBRIDGE, Mass. and SAN CARLOS, Calif., Sept. 25, 2019 /PRNewswire/ — Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical customers who order FoundationOne®CDx. The initial focus of the partnership …

Read More »

FDA Grants Merck KGaA’s Tepotinib Breakthrough Therapy Designation for Patients with Metastatic NSCLC with METex14 Skipping Alterations

DARMSTADT, Germany, Sept. 11, 2019 /PRNewswire/– Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its biopharmaceutical business as EMD Serono in the US and Canada, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational targeted therapy tepotinib* …

Read More »

Study Published by Clinical Cancer Research Shows PGDx’s Liquid Biopsy Predictive of PD-1 Blockade Response

BALTIMORE–(BUSINESS WIRE)–A study published by Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), shows Personal Genome Diagnostics Inc.’s (PGDx) liquid biopsy technology successfully detected microsatellite instability (MSI) in circulating tumor DNA (ctDNA), and was able to estimate the likelihood of both an immediate and durable response …

Read More »

Thermo Fisher Scientific Signs Agreement with Lilly for Companion Diagnostic to be Used with RET Inhibitor

CARLSBAD, Calif., Sept. 9, 2019 /PRNewswire/ — Thermo Fisher Scientific today announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved, next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and thyroid …

Read More »

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Investigational MEK Inhibitor

Ingelheim, Germany and Mumbai, India – 4 September 2019 – Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in …

Read More »

International Team Discovers Unique Pathway for Treating Deadly Children’s Brain Cancer

PHOENIX, Ariz. — Aug. 22, 2019 — An international team of researchers led by Yale University, University of Iowa, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has discovered a new pathway that may improve success against an incurable type of children’s brain cancer. The …

Read More »